Onkodok GmbH

Running trials

• Not yet recruiting

  Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

  NCT07004413· Phase 3· Source

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· Source

• Active, not recruiting

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· Phase 3· Source

• Recruiting

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab

  NCT05303532· Phase 3· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

  NCT05221840· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet prediction parameters identified in the PV-AIM project using artificial intelligence

  2022-502338-20-00· Phase 4· Source

• Active, not recruiting

  Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

  NCT04446117· Phase 3· Source

• Completed

  Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

  NCT04351256· Phase 2· Source